CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Acalabrutinib

Last Updated: March 11, 2021
Result type: Reports
Project Number: PC0211-000
Product Line: Reimbursement Review

Generic Name: Acalabrutinib

Brand Name: Calquence

Manufacturer: AstraZeneca Canada Inc

Therapeutic Area: Chronic Lymphocytic Leukemia (CLL)

Indications: ​As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy

Manufacturer Requested Reimbursement Criteria1: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

Submission Type: Initial

Tumour Type: Lymphoma

NOC Status at Filing: Post NOC

Project Status: Complete

Companion Diagnostics: No

Recommendation Type: Reimburse with clinical criteria and/or conditions

Fee Schedule1: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2